EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vibrating Mesh Nebulizer (A-VMN) Performance During Low-Flow Nasal Oxygen Therapy in Neonates

Rachel Burke, Mary Joyce, Elena Fernández Fernández, Brendan D Higgins iD, Ronan MacLoughlin iD

Pharmaceutics · 16.07.2026 · 18 (7) · 866

DOI: 10.3390/pharmaceutics18070866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 16.07.2026. Verfasst von Rachel Burke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Aerogen Ltd., Galway Business Park, Dangan, H91 HE94 Galway, Ireland. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Supplemental oxygen and aerosol therapy may be used simultaneously to treat neonates suffering from hypoxemia caused by respiratory diseases. Due to the cost and lack of availability of oxygen cylinders in some countries, oxygen concentrators are a reported substitute. We assessed whether an oxygen concentrator compared to low-flow oxygen therapy impacts neonatal aerosol drug delivery.

Methods

A vibrating mesh nebulizer (A-VMN; Aerogen Solo) was used to aerosolize a 500 µg dose of salbutamol. The aerosol was delivered via a nasal cannula to a neonate head model in combination with oxygen concentrator at gas flow rates of 0.2, 1.0, and 5.0 L per minute (LPM), and low-flow oxygen therapy at gas flow rates of 1.0, 4.0, and 5.0 LPM. Emitted and tracheal doses were recorded. The impact of A-VMN operation and refill on circuit pressure in both systems was also measured.

Results

The oxygen concentrator delivered a higher emitted dose than the low-flow system, the largest emitted dose (%) being 20.58 ± 0.50% and 14.69 ± 0.89%, respectively, at 1.0 LPM, p = 0.018. At 5.0 LPM, the tracheal dose was 11.01 ± 0.29% for the oxygen concentrator compared to 9.66 ± 1.53% for low-flow oxygen therapy, p = 0.073. Refill and operation of the A-VMN did not impact the circuit pressure in either system.

Conclusions

This study shows that the system used to provide concurrent aerosol and supplemental oxygen therapy has a significant impact on the quantity of nebulized drug delivered to patients.

Schlagwörter

Stichwörter der Autor:innen

aerosolneonateoxygen concentratoroxygen inhalation therapyvibrating mesh nebulizer

Autor:innen und Institutionen

  • Medical Affairs, Aerogen Ltd., Galway Business Park, Dangan, H91 HE94 Galway, Ireland.
  • Research and Development, Science and Emerging Technologies, Aerogen Ltd., Galway Business Park, Dangan, H91 HE94 Galway, Ireland.
  • Discipline of Physiology, School of Pharmacy and Medical Sciences, University of Galway, University Road, H91 W5P7 Galway, Ireland.
  • School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI), D02 YN77 Dublin, Ireland.
  • School of Pharmacy and Pharmaceutical Sciences, Trinity College, D02 PN40 Dublin, Ireland.

ORCID-Profile: Brendan D Higgins, Ronan MacLoughlin

Zitieren

APA

Burke, R., Joyce, M., Fernández Fernández, E., Higgins, B. D., & MacLoughlin, R. (2026). Vibrating Mesh Nebulizer (A-VMN) Performance During Low-Flow Nasal Oxygen Therapy in Neonates. Pharmaceutics, 18(7), 866. https://doi.org/10.3390/pharmaceutics18070866

Vancouver

Burke R, Joyce M, Fernández Fernández E, Higgins BD, MacLoughlin R. Vibrating Mesh Nebulizer (A-VMN) Performance During Low-Flow Nasal Oxygen Therapy in Neonates. Pharmaceutics. 2026;18(7):866. doi:10.3390/pharmaceutics18070866

BibTeX
@article{Burke2026,
  author = {Burke, Rachel and Joyce, Mary and Fernández Fernández, Elena and Higgins, Brendan D and MacLoughlin, Ronan},
  title = {Vibrating Mesh Nebulizer (A-VMN) Performance During Low-Flow Nasal Oxygen Therapy in Neonates},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {866},
  doi = {10.3390/pharmaceutics18070866}
}
Kostenlos starten →